Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Curvebeam AI Ltd. ( (AU:CVB) ) is now available.
CurveBeam AI Limited has secured A$6.5 million through an institutional placement of new shares, which will be used to fund sales, marketing, R&D, and supply chain costs for its HiRise™ device. Additionally, the company has entered a €10 million vendor financing agreement to support device placements in orthopaedic offices and is exploring distribution and manufacturing opportunities in China, potentially enhancing its market presence in North America, Europe, and Asia.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a developer and manufacturer of specialized medical imaging equipment, particularly CT devices, supported by AI-enabled SaaS-based clinical assessment solutions. The company focuses on providing point-of-care imaging solutions primarily for orthopaedic applications.
Average Trading Volume: 260,560
Technical Sentiment Signal: Sell
Current Market Cap: A$43.52M
Find detailed analytics on CVB stock on TipRanks’ Stock Analysis page.